Who are Fexinidazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Solosec, Pylera, BISMUTH SUBCITRATE POTASSIUM, Tindamax, Metro I.V. In Plastic Container, Metronidazole Vaginal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fexinidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fexinidazole — Competitive Intelligence Brief

Fexinidazole (FEXINIDAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole Antimicrobial [EPC]. Area: Hematology.

marketed Nitroimidazole Antimicrobial [EPC] Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Fexinidazole (FEXINIDAZOLE) — Sanofi. Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fexinidazole TARGET	FEXINIDAZOLE	Sanofi	marketed	Nitroimidazole Antimicrobial [EPC]		2021-01-01
Solosec	SECNIDAZOLE	Evofem Inc	marketed	Nitroimidazole Antimicrobial [EPC]		2017-01-01
Pylera	BISMUTH SUBCITRATE		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
BISMUTH SUBCITRATE POTASSIUM	BISMUTH SUBCITRATE POTASSIUM		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
Tindamax	TINIDAZOLE	Mission Pharma	marketed	Nitroimidazole Antimicrobial [EPC]		2004-01-01
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	marketed	Nitroimidazole Antimicrobial [EPC]		1963-01-01
Metronidazole Vaginal	Metronidazole Vaginal	Peking University Shenzhen Hospital	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-02-02 — Metro I.V. In Plastic Container · 8877792 · Formulation · US
2028-02-19 — Metro I.V. In Plastic Container · 7893097 · Formulation · US
2028-06-27 — Metro I.V. In Plastic Container · 8658678 · Method of Use · US
2032-06-28 — Metro I.V. In Plastic Container · 9198858 · Method of Use · US
2032-06-28 — Metro I.V. In Plastic Container · 8946276 · Method of Use · US
2032-06-28 — Metro I.V. In Plastic Container · 10238634 · Formulation · US
2032-06-28 — Metro I.V. In Plastic Container · 10596155 · Formulation · US
2039-01-16 — Metro I.V. In Plastic Container · 12257236 · Formulation · US
2039-10-04 — Metro I.V. In Plastic Container · 11541035 · Formulation · US

Sponsor landscape (Nitroimidazole Antimicrobial [EPC] class)

· 2 drugs in this class
Baxter · 1 drug in this class
Evofem Inc · 1 drug in this class
Mission Pharma · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fexinidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/fexinidazole. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab